A study led by researchers at the Johns Hopkins Kimmel Cancer Center has found that prostate cancer patients whose tumors contain a shortened protein called AR-V7 are less likely to respond to two widely used drugs for the condition. If large-scale studies validate the findings, the investigators say men with detectable blood levels of AR-V7 should avoid these two drugs and instead take other medicines to treat their prostate cancer. A report on the work is described ...
Read More
You have just read an article categorized health
titled Prostate Cancer Treatment Response can be Predicted by Blood Test for 'Nicked' Protein.
Written by:
editor -
Thursday, September 4, 2014
There are currently no comments for "Prostate Cancer Treatment Response can be Predicted by Blood Test for 'Nicked' Protein"
Post a Comment